39 results about "Myogenic cell" patented technology

The present invention provides a production method for a three-dimensional muscle tissue including the steps of: preparing an approximately rectangular first cell module containing skeletal myoblasts in a hydrogel, and having a plurality of approximately rectangular holes parallel to each other, and an approximately rectangular second cell module containing skeletal myoblasts in a hydrogel, and having a plurality of approximately rectangular holes parallel to each other at positions different from those of the first cell module in a vertical direction; alternately stacking the prepared first cell module and the prepared second cell module to obtain a stack; subjecting the skeletal myoblasts contained in the obtained stack to proliferation culture; and inducing the proliferated skeletal myoblasts to differentiate into myotubes.

This invention relates to the application of oridonin in the preparation of agents that improve muscle function, specifically by improving skeletal muscle dysfunction, enhancing insulin sensitivity, promoting myoblast differentiation into myotube cells, and / or increasing myoblast insulin sensitivity. Using an in vitro C2C12 myoblast model, this invention demonstrates that oridonin can promote myoblast differentiation and growth and increase C2C12 myoblast insulin sensitivity. Through an obesity-induced skeletal muscle dysfunction model, it is demonstrated that oridonin can improve skeletal muscle dysfunction and insulin resistance by increasing muscle strength, muscle endurance, muscle mass, and reducing muscle lipid accumulation. This invention provides new insights for drug research on improving skeletal muscle dysfunction and enhancing insulin sensitivity, and also enriches the pharmacological system of oridonin.

The present invention relates to a composition for the improvement and treatment of muscle diseases and cachexia, wherein diflunisal has the effect of promoting the differentiation and proliferation of myogenic cells, and further has the effect of improving and treating cachexia induced by chronic diseases such as muscle diseases or cancer through effects such as increased muscle mass and recovery of muscle strength.

The application discloses a kind of construction method and application of seawater fish muscle stem cell line, culture medium with basic medium as background medium;Culture medium includes LIF growth factor, EGF growth factor and leopard bristletooth-derived FGF2 protein;The final concentration of leopard bristletooth-derived FGF2 protein is 20~30 ng / mL, 30~45 ng / mL, 45~55 ng / mL or 55~70 ng / mL. Through the medium, immortalized seawater fish muscle stem cell line with good stability, cell division vigorous, short subculture time can be constructed, and can be stably subcultured for more than 50 generations. It provides raw materials for exploring the function of myoblasts, gene regulation mechanism, and provides the prerequisite for in vitro verification experiment for further exploring the influence of seawater fish muscle stem cells on growth rate, and lays a foundation for good strain breeding of seawater fish.

The invention discloses application of deaminotyrosine in improvement or prevention and treatment of muscular atrophy, and relates to the technical field of biological medicines. The invention finds that in the cellular level, DAT can effectively resist C2C12 myoblast senescence induced by etoposide; in a dexamethasone-induced C2C12 myotube atrophy model, DAT not only inhibits myotube diameter reduction from the form, but also down-regulates mRNA expression of key atrophy genes Atrogin-1 and MuRF-1 from the molecular level, and inhibits excessive activation of a ubiquitin-proteasome system; in-vivo animal experiments prove that DAT can reverse aging-related dyskinesia of rapidly-aged SAMP8 mice, and gait parameters of the rapidly-aged SAMP8 mice are all remarkably improved. According to the invention, a complete evidence chain from cells to the whole is constructed, and the DAT is proved to improve the senescent skeletal muscle atrophy through multiple ways of intervening cell senescence, antagonizing protein degradation, improving muscle microenvironment and the like, and shows important potential application value.

The present disclosure relates to an albumin nanocomposite comprising a phytochemical and a composition for muscle disease comprising the same, and more specifically, to an albumin nanocomposite comprising a phytochemical that exhibits an effect of inhibiting muscle loss caused by oxidative stress or inflammatory response and promoting the differentiation of myoblasts into muscle cells. The albumin nanocomposite comprising the phytochemical effectively delivers the phytochemical by targeting immune cells that induce reactive oxygen species and inflammatory responses. Accordingly, by regulating muscle-loss signaling pathways induced by reactive oxygen species and inflammatory responses, the nanocomposite inhibits muscle cell atrophy and promotes differentiation. Therefore, a composition comprising the albumin nanocomposite comprising the phytochemical according to the present disclosure can be provided as a composition for improving, preventing, or treating muscle diseases.

The invention discloses a method for separating, identifying and proliferating myoblasts of small-tailed han sheep, which comprises the following steps: (1) taking and treating skeletal muscle tissues: selecting healthy small-tailed han sheep, collecting the skeletal muscle tissues under sterile conditions, washing and cutting into pieces to obtain tissue blocks; (2) primary myoblast isolated culture: digesting, filtering and centrifuging the obtained tissue block, and culturing; (3) myoblast purification: purifying the cultured primary myoblasts to obtain purified myoblasts; (4) identifying myoblasts: identifying the obtained purified myoblasts; and (5) proliferation of myoblasts: after identification is completed, carrying out cell proliferation on the purified myoblasts obtained in the step (3) by utilizing a proliferation culture medium containing vitamin E. According to the method provided by the invention, high-purity and high-activity myoblasts can be obtained; vitamin E is utilized, so that the proliferation capacity of myoblasts can be remarkably improved, and the cell differentiation function of the myoblasts is not influenced.

The present invention relates to a phytochemical-containing albumin nanocomplex and a composition containing the same for improving muscle diseases. More specifically, the present invention relates to a phytochemical-containing albumin nanocomplex that has the effect of suppressing muscle loss caused by oxidative stress or inflammatory responses and promoting the differentiation of myoblasts into muscle cells. The phytochemical-containing albumin nanocomplex effectively delivers phytochemicals to immune cells that induce reactive oxygen species and inflammatory responses, thereby regulating the muscle loss signaling mechanism induced by reactive oxygen species and inflammatory responses, suppressing muscle cell atrophy, and promoting differentiation. This can improve muscle loss and prevent and treat muscle atrophy. Therefore, a composition containing the phytochemical-containing albumin nanocomplex of the present invention can be provided as a composition for improving muscle diseases.

Disclosed herein are systems and methods for testing effects of simulated microgravity on muscle structures. The system includes a clinostat and an adapter that is receivable into the clinostat. The adapter includes a housing that defines at least one receptacle. The system further includes an assembly having a substrate and a plurality of fibrils deposited on the substrate. The plurality of fibrils comprise collagen and extend along an axis. The assembly is receivable into a first receptacle of the at least one receptacle. The plurality of fibrils can have myoblasts thereon. Operation of the clinostat simulates microgravity. Test substances can screened using the muscle structures to determine effects on myogenesis.

The present invention relates to the use of a hemp seed extract for preventing or ameliorating muscle diseases by promoting myoblast differentiation or muscle regeneration. In the present invention, the hemp seed extract may exhibit preventive or therapeutic effects on various muscle diseases by increasing muscle mass, strengthening muscle power, improving muscle function, and enhancing exercise performance, and also has an effect of improving muscle function in healthy individuals in addition to treating muscle diseases.

The present invention relates to a composition for preventing, alleviating, or treating muscle diseases, the composition comprising an NFAT inhibitor as an active ingredient. An NFAT inhibitor (VIVIT peptide) comprising the amino acid sequence of SEQ ID NO: 1 according to the present invention was found to: alleviate the inhibition of muscle differentiation by suppressing NFAT signaling pathway activation induced by excessive calcium exposure, and increase the expression levels of muscle differentiation-related proteins in C2C12 myoblasts and mouse muscle-derived myoblasts. Thus, the NFAT inhibitor can be effectively used as a composition for preventing, alleviating, or treating muscle diseases.

The application discloses CircSESN1 a gene, an overexpression vector thereof, a specific primer pair, a detection kit and application thereof. CircSESN1 The application also discloses application of the gene, the overexpression vector, the specific primer pair or the fluorescent quantitative detection kit in regulation of chicken skeletal muscle growth and development. CircSESN1 The application further discloses a method for inhibiting proliferation and / or promoting differentiation of chicken myoblasts. The detection kit provided by the application can be used for detecting

This invention discloses a method for constructing and applying a marine fish muscle stem cell line. The culture medium uses basal medium as the background medium and contains LIF growth factor, EGF growth factor, and FGF2 protein derived from the leopard-gill sea bass. The final concentration of FGF2 protein from the leopard-gill sea bass is 20-30 ng / mL, 30-45 ng / mL, 45-55 ng / mL, or 55-70 ng / mL. Passaging using this medium can construct a stable, rapidly dividing, and short-passaging immortalized marine fish muscle stem cell line, capable of stable passage for more than 50 generations. This provides raw materials for exploring the function and gene regulation mechanisms of myoblasts, and provides in vitro verification experimental conditions for further research on the effects of marine fish muscle stem cells on growth rate, laying the foundation for the breeding of superior marine fish species.

The application discloses functions and application of KIF5B gene in regulating physiological activity of myoblasts, and belongs to the technical field of animal cell culture. By investigating influences of KIF5B knockdown and overexpression on proliferation of myoblasts, it is found that KIF5B knockdown can significantly inhibit DNA synthesis speed of myoblasts, thereby inhibiting proliferation. In addition, overexpression of KIF5B can significantly inhibit expression of MYOD and MYOG, improve DNA synthesis speed of myoblasts, thereby significantly improving proliferation rate of myoblasts. The application provides an important key molecular target and technical support for efficient and rapid culture of myogenic cells.

The application belongs to the technical field of poultry breeding, and discloses siRNA for targeted inhibition of chicken ULK2 expression and application thereof; the siRNA comprises ULK2-1170; the siRNA for targeted inhibition of chicken ULK2 gene expression can effectively reduce the expression of the chicken ULK2 gene after being transferred into chicken primary myoblast cells, the inhibition efficiency is more than 50%, and the knockdown efficiency is very high; the siRNA can be used for identifying gene functions by specifically knocking down the expression of the chicken ULK2 gene in vitro, and can be applied to genetic selection of high-quality broiler leg muscle development as a molecular marker, and has great economic value and scientific research value.

The application discloses a use and application based on CDKN1A influence on proliferation and differentiation of goat skeletal muscle, relates to the field of agricultural genetic engineering, and discloses that iRNA-seq and RNA-seq technology reveals mRNA expression maps of the longest dorsal muscle of 5-month-old Hainan black goats and 24-month-old Hainan black goats in two development stages, and CDKN1A with differential expression is screened out; the CDKN1A gene is used for negatively regulating proliferation of goat myoblasts; and the application finds that CDKN1A has a regulation effect on proliferation and differentiation of skeletal muscle cells of Hainan black goats, and can be applied to development and utilization of germplasm resources of the breed and seed selection and breeding.

The invention discloses a composition for promoting myotube formation and maintaining muscle health. The problem that in the prior art, leucine or a simple combination of leucine and other BCAA is poor in muscle regeneration promoting effect is solved. A composition for promoting myotube formation and maintaining muscle health includes leucine, isoleucine, and alpha-ketoglutaric acid. The invention proves that the combination of the three has a remarkable combination effect in promoting myoblasts to differentiate into myotubes. The test data shows that the differentiation promoting effect of the combination of the three components is obviously better than that of any single component or double component combination, and the cell proliferation test proves that the composition has no obvious influence on the proliferation of C2C12 myoblasts and even eliminates toxic interference at high concentration. It is shown that the beneficial effect of promoting the increase of myotube number is specifically achieved by enhancing the differentiation process of cells rather than simple proliferation promoting action and pointing to more mature muscle function formation, and therefore the composition can be applied to the situation that muscle regeneration needs to be promoted, and muscle atrophy is improved or prevented.

This invention relates to the application of *Hirudo medicinalis* in the preparation of drugs that promote skeletal muscle cell differentiation and / or prevent muscle atrophy, belonging to the field of biomedical technology. The skeletal muscle cells are myoblasts. In vitro, this drug can promote differentiation by upregulating the expression of myosin heavy chain (MyHC), myogenin, and myogenic determinant MyoD, thereby increasing myotube diameter. In vivo, it can improve doxorubicin-induced skeletal muscle atrophy in mice and repair muscle fiber damage caused by natural aging nematodes. The chemotherapeutic drug is doxorubicin, which can exert an anti-atrophy effect by maintaining the expression of myosin heavy chain (MyHC) and improving myotube morphology damage. This invention is the first to discover and experimentally demonstrate that *Hirudo medicinalis* freeze-dried powder has the activity of promoting myoblast differentiation and preventing muscle atrophy, opening up new applications for traditional Chinese medicine leeches in the prevention and treatment of muscle atrophy and expanding the medicinal value of *Hirudo medicinalis*.

The invention discloses a traditional Chinese medicine composition for enhancing functions of mature skeletal muscle cells and application of the traditional Chinese medicine composition. The composition is prepared from ginseng, astragalus membranaceus, pericarpium citri reticulatae, dogwood and rhizoma polygonati according to a specific ratio. The invention also provides an establishment method based on the quality standard of various active components (ginsenoside Rg1, hesperidin and the like) in the composition. The traditional Chinese medicine composition disclosed by the invention does not have a remarkable activity promoting effect on undifferentiated C2C12 myoblasts in a proliferation period, but can specifically enhance the cell activity of differentiated mature C2C12 myotubular cells. The action characteristics of the cell state dependence show that the composition does not simply stimulate cell proliferation, but is targeted to improve the functional state of mature muscle cells, so that a high-precision solution is provided for treating diseases (such as sarcopenia) characterized by mature muscle fiber function decline.

The application discloses a starch-based edible scaffold and a preparation method and application thereof, and belongs to the technical field of cell scaffold materials. The edible starch is used as a base material, and a semi-interpenetrating network (Semi-IPN) hydrogel scaffold is constructed through heat-induced self-assembly, and the scaffold has good biocompatibility and edible safety. The preparation method can accurately control the elastic modulus and mechanical properties of the scaffold, so that the scaffold is suitable for providing tensile stress stimulation for fish myoblasts. Thanks to the above-mentioned characteristics, the scaffold can not only effectively support the adhesion and proliferation of fish myoblasts, but also significantly promote the directional differentiation of the fish myoblasts, and form a biomimetic muscle tissue. The application provides an innovative and performance-controllable cell scaffold solution for producing fish culture meat products which do not need to be separated from the scaffold and can be directly eaten.

Systems, apparatuses, methods, and computer program products are described herein for performing embedded printing of thick structured meat constructs. Bioinks can be formed from mixing myoblasts and a hydrogel precursor with a porous microgel to form a myoblast-microgel composite ink and from mixing adipocyte progenitor cells and a hydrogel precursor with a solid microgel to form an adipocyte progenitor cell-microgel composite ink. A cellular yield-stress support matrix material can be formed by mixing adipose-derived stem cells, endothelial cells, support cells, and a hydrogel precursor with a porous microgel. A thick, structured, meat construct can be formed by iteratively printing, into the cellular yield-stress matrix material, the myoblast-microgel composite ink to form muscle portions, the adipocyte progenitor cell-microgel composite ink to form lipid portions, and a sacrificial ink to form vascular network portions. Sacrificial ink is then removed to define a perfusable vascular network through the thick structured meat construct.

Provided herein are compositions, kits, and methods for manufacturing cells for treating or regenerating damaged or diseased tissue comprising engineered fibroblasts, myoblasts, osteocytes, chondrocytes, adipocytes, epithelial cells, or mesenchymal stem cells that overexpress glucose transporter 5 (GLUTS).

The invention discloses a wheat peptide with muscle and weight gaining effects, a composition containing the wheat peptide as well as a preparation method and application of the wheat peptide, and relates to the technical field of food processing. The wheat peptide with the muscle and weight gaining effect is obtained by performing enzymolysis on wheat protein by adopting serine protease, trypsin and flavourzyme and then adding papain for enzymolysis. The wheat peptide can promote myoblast proliferation, improve the holding power and weight of mice, and effectively improve the relative level of IGF-1 in serum. In addition, the vitamin B6 and the vitamin B6 can cooperate to promote the absorption of whey protein.

本发明属于生物医药技术领域，具体涉及一种小分子化合物在制备改善肌肉衰减药物中的应用。本发明使用地塞米松诱导小鼠成肌细胞C2C12产生肌肉衰减模型，通过CCK8活性检测，Western Blot检测肌少症相关蛋白表达情况。通过以上检测指标综合评估小分子化合物在制备改善肌肉衰减的作用。实验结果证明，小分子化合物SY‑4（Syringaresinol，丁香脂素）和 / 或SY‑35（Vomifoliol，吐叶醇）对细胞无明显毒性作用，同时显著降低了肌肉降解蛋白（Murf1）的表达量，并提升了肌肉合成蛋白（MyOD）的表达水平，具有很好的肌肉衰减治疗潜力，可以用于制备改善肌肉衰减药物。

This invention relates to the field of cell biotechnology, specifically to a method for large-scale preparation of cultured meat using a pilot-scale standardized bioreactor. The method includes the following steps: preparing photocurable microcarriers using gelatin and a photoinitiator; mixing large yellow croaker myoblasts, large yellow croaker preadipocytes, and the photocurable microcarriers, and then inoculating the mixture into a pilot-scale standardized bioreactor for culture; collecting the cell-bearing microcarriers cultured in the pilot-scale standardized bioreactor; and processing the cell-bearing microcarriers using a mold to prepare cultured meat. This invention uses large yellow croaker myoblasts, large yellow croaker preadipocytes, and photocurable microcarriers as experimental materials. Through a specific culture process, the pilot-scale standardized bioreactor is set up. By utilizing real-time monitoring and control of the culture conditions in the pilot-scale standardized bioreactor, the suspension co-culture of two types of large yellow croaker stem cells on photocurable microcarriers is achieved. Large-sized cultured meat is then prepared through mold processing.

This invention discloses an anti-muscle aging composition containing theaflavins (TF) from black tea extract and phytosterols, and its applications, belonging to the biomedical field. The composition consists of theaflavins (TF) and phytosterols (PS). Experimental verification showed that theaflavins at 1 μM and phytosterols at 1000 ppm exhibited a significant synergistic protective effect against D-galactose-induced senescence of C2C12 myoblasts. Experimental results also showed that the composition significantly enhanced cell viability and inhibited the accumulation of reactive oxygen species (ROS), with a cell viability synergistic coefficient of 0.034 and a ROS oxidative stress synergistic coefficient of 0.366, both demonstrating strong synergistic effects. The composition provided by this invention can be used to prepare drugs, functional foods, or nutritional supplements for the prevention, improvement, and / or treatment of muscle aging, featuring safety, high efficiency, and readily available raw materials, providing a new direction for the development of anti-muscle aging related products.

The invention belongs to the technical field of biology, and particularly relates to a culture medium capable of differentiating and inducing amniotic fluid cells into myoblasts, a method and application. The culture medium contains 5% v / v serum, 0.1 [mu] M of dexamethasone, 50 [mu] M of hydrocortisone, 1 [mu] M of MCHIR99021 and 5-10 ng / mL of IGF-1, and a solvent is a low-sugar DMEM (Dulbecco Modified Eagle Medium). According to the invention, amniotic fluid cells are separated from amniotic fluid, and myoblasts can be obtained by using the culture medium to culture, differentiate and induce. According to the invention, efficient muscle differentiation and RYR1 gene overexpression of amniotic fluid cells are realized for the first time, and the gene has high fidelity on splicing variation after induced differentiation, so that a safe, rapid and low-cost solution is provided for prenatal clear gene diagnosis.

This invention discloses the application of Anemarrhena saponin A-III in the preparation of drugs for treating sarcopenia. This invention is the first to discover that Anemarrhena saponin A-III can significantly promote the growth of C2C12 myocytes into myotubes, improve autophagy function, and reduce lipid deposition; it can strengthen muscle function, alleviate the morphology of the gastrocnemius muscle in sarcopenia model mice, and increase muscle fiber area, thereby effectively combating sarcopenia. This provides an effective approach for the treatment of sarcopenia.

The invention discloses a bovine circular RNA circARHGAP10 for coding a protein and an application of the bovine circular RNA circARHGAP10. According to the invention, a gene sequence for forming an annular structure of circARHGAP10 is found, and it is verified that the protein ARHGAP10-202aa coded by the gene sequence can promote differentiation of bovine myoblasts, so that a new target spot is provided for molecular regulation and control of skeletal muscle development. In addition, recombinant plasmids for expressing ARHGAP10-202aa are locally injected into muscle injury parts and serve as medicine components for treating muscle injury, and it is found that regeneration and repair of injured muscles can be remarkably promoted after administration.

This invention discloses the application of a traditional Chinese medicine composition in the preparation of a drug for treating sarcopenia, wherein the traditional Chinese medicine composition consists of Astragalus membranaceus and Anemarrhena asphodeloides. The study found that the combination of Astragalus membranaceus and Anemarrhena asphodeloides can significantly improve the differentiation function of C2C12 myoblasts induced by high glucose and inhibit lipid deposition, and improve skeletal muscle mass, muscle strength, and motor function in a streptozotocin-induced C57BL / 6 diabetic sarcopenia mouse model. In vitro and in vivo experiments have confirmed that this drug has significant effects in improving muscle atrophy, enhancing motor function, and restoring muscle strength; it can effectively increase the cross-sectional area of ​​muscle fibers, promote myotube fusion, and accelerate damage repair, showing a clear potential to inhibit diabetic muscle atrophy. This provides an effective traditional Chinese medicine compound intervention strategy for the clinical treatment of diabetic sarcopenia and has good prospects for development and application.